20/20 Biolabs, Inc. Common Stock (AIDX)vsMedtronic PLC (MDT)
AIDX
20/20 Biolabs, Inc. Common Stock
$0.55
+5.86%
HEALTHCARE · Cap: $5.60M
MDT
Medtronic PLC
$91.27
+0.76%
HEALTHCARE · Cap: $109.30B
Smart Verdict
WallStSmart Research — data-driven comparison
Medtronic PLC generates 1971169% more annual revenue ($36.36B vs $1.84M). MDT leads profitability with a 13.2% profit margin vs -279.1%. MDT earns a higher WallStSmart Score of 62/100 (C+).
AIDX
Avoid21
out of 100
Grade: F
MDT
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AIDX.
Margin of Safety
+1.1%
Fair Value
$91.54
Current Price
$91.27
$0.27 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 22.1%
Generating 2.1B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -354.6% — below average capital efficiency
Expensive relative to growth rate
Grey zone — moderate risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AIDX
The strongest argument for AIDX centers on Price/Book.
Bull Case : MDT
The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin.
Bear Case : AIDX
The primary concerns for AIDX are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : MDT
The primary concerns for MDT are PEG Ratio, Altman Z-Score.
Key Dynamics to Monitor
AIDX profiles as a turnaround stock while MDT is a value play — different risk/reward profiles.
MDT carries more volatility with a beta of 0.57 — expect wider price swings.
MDT is growing revenue faster at 9.9% — sustainability is the question.
MDT generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
MDT scores higher overall (62/100 vs 21/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
20/20 Biolabs, Inc. Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
20/20 Biolabs, Inc. (AIDX) is a pioneering biotechnology company dedicated to advancing genomic research and diagnostics through its cutting-edge laboratory services. Focused on improving the accuracy and efficiency of genetic testing for both clinical and research applications, the company is set to establish itself as a leader in the molecular diagnostics market. With a strategic emphasis on personalized medicine and a robust portfolio of state-of-the-art technologies, 20/20 Biolabs is well-positioned to meet the surging demand for genomic data and capitalize on emerging opportunities within the dynamic biotechnology landscape. Its innovative approach and strong market presence reflect a promising growth trajectory in an industry characterized by rapid advancements.
Medtronic PLC
HEALTHCARE · MEDICAL DEVICES · USA
Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?